Hello Sir,

Hope you are doing well.

In order to recommend the best stock ideas to our members for their portfolios, our team does extensive research, goes through all the corporate announcements on daily basis and screens for various potential investment opportunities.

Through [Stocks to watch] email, we would like to share with you interesting stock updates we come across while performing our research. Hope you find them useful for your own investments or to add the stocks to your watchlist:

 

Before that, if you are interested in investing in a Pharmaceutical company which has made an extremely complex and poisonous material from scratch (with a worldwide market potential of Rs 27,000 crore +) and is the only Indian maker, you can read about it here - LINK

 

La Opala Rg – La Opala is a very well known brand and a leading manufacturer and marketer of tableware (opal and glass) in India.

On 28th Apr'22 we came across an announcement by La Opala regarding inauguration of New Green Field plant on 27th Apr'22.

Source: BSE India

Key highlights of the same are as follows:

  • Production is likely to commence by the end of the Jun'22 quarter
  • The production capacity of the new plant is 11,000 metric tons per annum (MTPA)
  • Existing capacity of the company is 26,000 MTPA so the new plant will bring about 40% addition in capacity

La Opala is currently trading around the same levels as it was in Sep'15.

20 Microns – If you are into tiny, obscure, off the radar companies, you will love reading the latest Press release of 20 Microns released on 4th May'22.

Key highlights of the same are as follows:

  • For FY 22, the company has reported 27% growth in sales on YOY basis, 36% growth in EBITDA, 119% growth in PBT and 51% growth in PAT
  • The company has exited from CDR (corporate debt restructuring) and the pledged shares of the promoters have been released
  • The company could offset the impact of higher RM and freight cost with higher sales of specialty chemicals
  • Management intends to grow EBITDA margin by increasing contribution of higher margin products and focusing on exports
  • Management expects to sustain ROCE around 20% and operating margin in the range of 13-15%
  • Management expects to substantially reduce its long term debt by FY 24

 

Disclaimer: This is not a recommendation to buy/sell La Opala and 20 Microns. These updates are as announced by the companies on exchanges and only for the purpose of information and education. I have personal investment in 20 microns.

If you are looking for investment opportunities do check out our premium subscriptions. 

 

 

Best Regards,

Ekansh Mittal
Research Analyst
Web: https://www.katalystwealth.com/

 

SEBI Research Analyst Registration No. INH100001690
Research Analyst Details

Name: Ekansh Mittal     Email Id: [email protected]    Ph: +91 727 5050062

Details of Associate: Not Applicable

Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer: http://www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690

The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.

The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.

We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.

Disclaimer: You can access it here - LINK

Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – Yes, in 20 Microns

Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No

Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No

Whether it or its associates have received any compensation from the subject company in the past twelve months – No

Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No

Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No

Whether the research analyst has served as an officer, director or employee of the subject company – No

Whether the research analyst or research entity has been engaged in market making activity for the subject company – No